Pfizer (PFE) Offering Possible 5.26% Return Over the Next 6 Calendar Days

Pfizer's most recent trend suggests a bullish bias. One trading opportunity on Pfizer is a Bull Put Spread using a strike $37.00 short put and a strike $32.00 long put offers a potential 5.26% return on risk over the next 6 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $37.00 by expiration. The full premium credit of $0.25 would be kept by the premium seller. The risk of $4.75 would be incurred if the stock dropped below the $32.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Pfizer is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Pfizer is bullish.

The RSI indicator is at 69.93 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Pfizer

Gilead Tops List of Most Innovative Drug Companies
Thu, 12 Sep 2019 21:46:53 +0000
Index ranks ability of pharma companies to bring drugs from early testing to market and make them successful Continue reading…

5 Companies Growing Earnings
Wed, 11 Sep 2019 20:53:38 +0000
Pfizer tops the list Continue reading…

Dow Jones Today: Plenty of Good News
Wed, 11 Sep 2019 20:15:57 +0000
With the help of broad-based leadership, the major U.S. equity benchmarks rallied Wednesday amid a flurry of decent headlines. Today's leadership came by way of the technology and healthcare sectors, the two largest sector weights in the S&P 500, with some contributions from the defensive, high-yielding utilities group.Source: Shutterstock President Donald Trump took to Twitter (NYSE:TWTR), something that doesn't always end well for investors, to encourage the Federal Reserve to take interest rates to zero or even negative. It's unlikely the Fed follows the advice of going to negative rates, at least not anytime soon, but another rate cut does appear imminent if Fed funds futures are to be believed. * 10 Stocks to Sell in Market-Cursed September Adding to today's ebullience was news out of China that the country will exempt certain U.S. goods from 25% tariffs that were deployed last year. This is the latest sign that the trade talks the two countries are expected to hold next month could actually happen and that the results could be positive.InvestorPlace – Stock Market News, Stock Advice & Trading TipsThose catalysts were enough to send the Nasdaq Composite higher by 1.06% while the S&P 500 gained 0.72%. The Dow Jones Industrial Average jumped 0.85%. Much of the strength in the blue chip index was attributable to its larger components as, in late trading, just 16 of the Dow's 30 residents were trading to the upside. Boeing Triumphs AgainTry as I might to mention different Dow names from day-to-day, Boeing (NYSE:BA) is the index's largest component and when it's the best-performing Dow stock on a given day, as it was Wednesday, it bears mentioning.The aerospace and defense giant rallied 3.50% today after CEO Dennis Muilenberg made some positive though not earth-shattering comments about Boeing's efforts to get the 737 MAX jet back in the skies."We're continuing to make solid progress on return to service," said the CEO at an investor conference in California. "We're actively engaged with regulators around the world and day-to-day working with the FAA on return-to-service timing." AAPL Stock Hits $1 Trillion AgainA day after its new product launch event, Apple (NASDAQ:AAPL) performed better than it did yesterday, gaining 3.18% to rank as the second-best Dow performer behind Boeing, pushing the stock back into the exclusive $1 trillion market value club for the first time this year. Predictably, analysts were chatty about Apple stock today following news of iPhone enhancements and that the Apple + streaming service will be less expensive, at least for now, than competing options.Needham analyst Laura Martin reiterated her "strong buy" rating on Apple stock while boosting her price target to $250 from $225, implying upside of more than 10% from Wednesday's close. Encouraging SignAs noted earlier, the healthcare sector was a big contributor the broader market's Wednesday upside and three of the Dow's four healthcare names traded higher today with Pfizer (NYSE:PFE) being the only offender of the quartet.Granted, it's just one day, but it's nice to see some strength in the pharmaceuticals stocks because this group could face more headwinds as the 2020 presidential campaign unfolds. With that in mind, House Democrats are looking for ways cobble together a plan that would alter how Medicare pays for drugs while President Trump has and will continue to tout falling drug prices.While brand name prices are still increasing, the president can lean on declining generic prices in what is sure to be a hot-button campaign issue. This is a bipartisan issue, rare as those are, and that presents some risks going forward. Bottom Line in Dow Jones TodayI recently mentioned signs that value stocks are making a comeback against their growth rivals. Some market observers may overstate the consequences in that scenario. It's not all bad when considering decent percentages of the Dow Jones Industrial Average and S&P 500 are classified as value stocks.What would be positive for the sustainability of this mini-rally is strength in maligned small caps and that scenario is emerging. The Russell 2000 Index jumped more than 2% and that could be a sign stocks are poised to defy usually gloomy September expectations. Importantly, that index came into Wednesday with a gain of almost 5% over the past week.Todd Shriber does not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Sell in Market-Cursed September * 7 of the Worst IPO Stocks in 2019 * 7 Best Stocks That Crushed It This Earnings Season The post Dow Jones Today: Plenty of Good News appeared first on InvestorPlace.

Leaner Pfizer Positioned to Boost R&D Output
Wed, 11 Sep 2019 19:50:48 +0000
Company’s recent decisions will enable it to concentrate on building core business Continue reading…

4 Big Drugmakers Boasting Impressive Oncology Pipelines
Wed, 11 Sep 2019 13:32:01 +0000
We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.